New drug duo aims to keep leukemia away after stem cell transplant
NCT ID NCT07101588
First seen Mar 20, 2026 · Last updated May 27, 2026 · Updated 11 times
Summary
This study tests whether adding two drugs, ruxolitinib and decitabine, to the usual chemotherapy before a stem cell transplant can lower the chance of acute myeloid leukemia coming back. About 200 patients aged 12–64 with high-risk leukemia in first remission will take part. The approach aims to improve long-term control of the disease, but lifelong monitoring and possible medications are still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.